These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33074018)

  • 21. The role of Real-World Data and evidence in oncology medicines approved in EU in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    J Cancer Policy; 2023 Jun; 36():100424. PubMed ID: 37116794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer.
    Saesen R; Kantidakis G; Marinus A; Lacombe D; Huys I
    Front Pharmacol; 2022; 13():969778. PubMed ID: 36091761
    [No Abstract]   [Full Text] [Related]  

  • 23. Use of Real-World Data and Evidence in Drug Development of Medicinal Products Centrally Authorized in Europe in 2018-2019.
    Eskola SM; Leufkens HGM; Bate A; De Bruin ML; Gardarsdottir H
    Clin Pharmacol Ther; 2022 Jan; 111(1):310-320. PubMed ID: 34689334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
    Phillips CM; Parmar A; Guo H; Schwartz D; Isaranuwatchai W; Beca J; Dai W; Arias J; Gavura S; Chan KKW
    Cancer; 2020 Apr; 126(8):1717-1726. PubMed ID: 31913522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
    Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
    Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of Real-World Evidence for Regulatory Decisions in China.
    Xu J; Wu W; Zhang X; Ren Y; Yao M; Liu M; Zou K; Wang W; Sun X
    Clin Pharmacol Ther; 2024 Jul; 116(1):82-95. PubMed ID: 38566457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report on the current status of the use of real-world data (RWD) and real-world evidence (RWE) in drug development and regulation.
    Breckenridge AM; Breckenridge RA; Peck CC
    Br J Clin Pharmacol; 2019 Sep; 85(9):1874-1877. PubMed ID: 31290181
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group.
    Dai WF; de Oliveira C; Blommaert S; Pataky RE; Tran D; Aurangzeb Z; Kendell C; Folkins C; Somayaji C; Dowden J; Cheung W; Strumpf E; Beca JM; McClure C; Urquhart R; McDonald JT; Alvi R; Turner D; Peacock S; Denburg A; Mercer RE; Muñoz C; Parmar A; Tadrous M; Takhar P; Chan KKW; On Behalf Of The CanREValue Collaboration
    Curr Oncol; 2022 Mar; 29(3):2046-2063. PubMed ID: 35323365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Understanding Use of Real-World Data and Real-World Evidence to Support Regulatory Decisions on Medical Product Effectiveness.
    Mahendraratnam N; Mercon K; Gill M; Benzing L; McClellan MB
    Clin Pharmacol Ther; 2022 Jan; 111(1):150-154. PubMed ID: 33891318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Regulatory Approval Status on CADTH Reimbursement of Oncology Drugs and Role of Real-World Evidence on Conditional Approvals from 2019 to 2021.
    Lau C; Dranitsaris G
    Curr Oncol; 2022 Oct; 29(11):8031-8042. PubMed ID: 36354695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World.
    McNair D; Lumpkin M; Kern S; Hartman D
    Clin Pharmacol Ther; 2022 Jan; 111(1):44-51. PubMed ID: 34655224
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-World Evidence in the Real World: Beyond the FDA.
    Krause JH; Saver RS
    Am J Law Med; 2018 May; 44(2-3):161-179. PubMed ID: 30106647
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The FDA Oncology Center of Excellence and precision medicine.
    Goldberg KB; Blumenthal GM; McKee AE; Pazdur R
    Exp Biol Med (Maywood); 2018 Feb; 243(3):308-312. PubMed ID: 29105511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluating the Use of Nonrandomized Real-World Data Analyses for Regulatory Decision Making.
    Franklin JM; Glynn RJ; Martin D; Schneeweiss S
    Clin Pharmacol Ther; 2019 Apr; 105(4):867-877. PubMed ID: 30636285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Commercial impact of adding real-world evidence to clinical trials at regulatory approval: a Markovian-like transition model.
    Jandhyala R
    Curr Med Res Opin; 2023 Dec; 39(12):1559-1566. PubMed ID: 36715502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leveraging Real-World Evidence: A Paradigm Shift in Regulation.
    De S; Larson L; Kelly K; Hanson B; Mack CD
    J Orthop Trauma; 2021 Mar; 35(Suppl 1):S13-S16. PubMed ID: 33587541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world evidence for regulatory decision-making: updated guidance from around the world.
    Burns L; Le Roux N; Kalesnik-Orszulak R; Christian J; Dudinak J; Rockhold F; Khozin S; O'Donnell J
    Front Med (Lausanne); 2023; 10():1236462. PubMed ID: 38020096
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact.
    Brown JP; Douglas IJ; Hanif S; Thwaites RMA; Bate A
    Value Health; 2021 Sep; 24(9):1241-1244. PubMed ID: 34452702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Framework for Methodological Choice and Evidence Assessment for Studies Using External Comparators from Real-World Data.
    Gray CM; Grimson F; Layton D; Pocock S; Kim J
    Drug Saf; 2020 Jul; 43(7):623-633. PubMed ID: 32440847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.